Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

US pharmaceutical giant Pfizer's new research and development (R&D) centre officially opened at BioPark in the Beijing Economic-Technological Development Area (BDA).As the company's third R&D centre ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

The scientists trying to find a cure for cancer know they have to be patient. Likewise, most shareholders who back companies ...

Commentary: New York must take on Big Pharma by demanding more transparency in pricing and ensuring generics aren't delayed ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the ...

However, Pfizer's foundation remains solid, based on strong cash flow generated from a diverse basket of drugs. The company's large size confers significant competitive advantages in developing ...